Rep. Eshoo Statement on COVID-19 Vaccine Emergency Use Authorization

December 11, 2020
Press Release

WASHINGTON, D.C. – House Health Subcommittee Chairwoman Anna G. Eshoo (D-CA) released the following statement today after the Food and Drug Administration (FDA) authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use in people 16 years or older:

“Today is a historic milestone in the fight against the COVID-19 pandemic. The FDA authorized the first COVID-19 vaccine for emergency use, meaning that millions of Americans could begin to receive vaccinations within days. The FDA authorized the vaccine after reviewing thousands of pages of clinical trial and manufacturing data and receiving a positive recommendation from an advisory committee of independent scientific experts. A blinded, randomized, placebo-controlled phase 3 clinical trial showed the Pfizer-BioNTech vaccine to be 95% effective in preventing COVID-19 while meeting rigorous safety standards. Bravo to the career scientists and physicians at the FDA that resisted tremendous political interferences, and to Pfizer and BioNTech for their tireless efforts to develop a vaccine to address a virus claiming the lives of countless  people around the world.”

“As we move to the vaccination phase, we must continue to allow scientists and public health officials lead the way. Soon the Centers for Disease Control and Prevention will vote on whether to prioritize vaccinations for health care workers and those in long-term care facilities and states and the federal government will work together to distribute the vaccine in an equitable manner. More work remains, but today’s news is cause for celebration during the darkest month yet of rising infections and soaring deaths across our country.”

# # #